Institutional shares held 67.3 Million
1.72M calls
186K puts
Total value of holdings $979M
$25M calls
$2.7M puts
Market Cap $45.2B
3,109,050,112 Shares Out.
Institutional ownership 2.16%
# of Institutions 363


Latest Institutional Activity in TAK

Top Purchases

Q2 2025
Qrg Capital Management, Inc. Shares Held: 433K ($6.3M)
Q2 2025
Sivia Capital Partners, LLC Shares Held: 22.7K ($331K)
Q2 2025
Merit Financial Group, LLC Shares Held: 18.2K ($265K)
Q2 2025
Empirical Financial Services, LLC D.B.A. Empirical Wealth Management Shares Held: 28.4K ($413K)
Q2 2025
Hb Wealth Management, LLC Shares Held: 12.9K ($188K)

Top Sells

Q2 2025
Clean Yield Group Shares Held: 275K ($4M)
Q2 2025
Highland Capital Management, LLC Shares Held: 61.3K ($891K)
Q2 2025
Truist Financial Corp Shares Held: 65.1K ($948K)
Q2 2025
Investors Research Corp Shares Held: 44.5K ($648K)
Q2 2025
Nbc Securities, Inc. Shares Held: 55.4K ($807K)

About TAK

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.


Insider Transactions at TAK

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
0 Shares
From 0 Insiders
Sell / Disposition
0 Shares
From 0 Insiders

Track Institutional and Insider Activities on TAK

Follow TAKEDA PHARMACEUTICAL CO LTD and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TAK shares.

Notify only if

Insider Trading

Get notified when an Takeda Pharmaceutical CO LTD insider buys or sells TAK shares.

Notify only if

News

Receive news related to TAKEDA PHARMACEUTICAL CO LTD

Track Activities on TAK